INS and fatty liver disease: Some of the modifications include improvement in insulin sensitivity and glucose tolerance, decrease in body weight, decrease in hepatic steatosis, white adipose tissue (WAT) beigeing, and an increase in WAT eosinophils and M2 macrophages with increased expression of M2 markers (Ym1 and Arg1).